Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has earned a consensus recommendation of “Hold” from the twelve research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $7.31.

A number of equities analysts have issued reports on the stock. Robert W. Baird lowered shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th. Guggenheim started coverage on Maravai LifeSciences in a research report on Thursday, December 19th. They issued a “neutral” rating for the company. The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their target price for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th. Bank of America reduced their price objective on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Finally, UBS Group lowered their target price on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a report on Friday, March 21st.

Maravai LifeSciences Trading Up 3.0 %

Shares of Maravai LifeSciences stock opened at $2.37 on Thursday. The firm has a market capitalization of $598.49 million, a price-to-earnings ratio of -1.45 and a beta of -0.08. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The firm’s 50 day simple moving average is $3.82 and its two-hundred day simple moving average is $5.68. Maravai LifeSciences has a 12-month low of $2.07 and a 12-month high of $11.56.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the sale, the general counsel now owns 167,618 shares of the company’s stock, valued at approximately $843,118.54. This represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.63% of the stock is owned by corporate insiders.

Institutional Trading of Maravai LifeSciences

A number of institutional investors have recently bought and sold shares of MRVI. Performa Ltd US LLC lifted its holdings in shares of Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,300 shares during the last quarter. FNY Investment Advisers LLC increased its stake in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after acquiring an additional 6,000 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Maravai LifeSciences by 3,541.4% during the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock worth $56,000 after buying an additional 9,916 shares in the last quarter. Cibc World Markets Corp acquired a new stake in Maravai LifeSciences in the fourth quarter valued at $56,000. Finally, Atria Investments Inc purchased a new stake in Maravai LifeSciences during the fourth quarter worth about $58,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.